The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
The cash and debt free consideration value is €370 million.
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Subscribe To Our Newsletter & Stay Updated